Navigation Links
Drug-Coated Stents Reduce Repeat Artery Procedures
Date:6/24/2008

But sicker patients may be getting bare metal devices, study suggests

TUESDAY, June 24 (HealthDay News) -- Heart patients who got drug-coated stents did better than those who received the bare-metal kind of stent, a major study found.

But it isn't a simple either-or issue, the study authors said.

The researchers compared the experience of almost 39,000 Medicare recipients who underwent non-emergency stenting between October 2002 and March 2003, when only bare-metal stents were available, with that of more than 28,000 patients who got stents from September through December 2003. During the later time period 61.5 percent of patients received drug-coated stents.

A stent is a tiny tube placed into an artery or blood vessel to keep the vessel open.

Only one coated stent -- Cordis Corp.'s sirolimus-coated Cypher -- was available in 2003. Over a two-year follow-up period, 22.8 percent of the people in the bare-stent era required a repeat procedure to open a blocked coronary artery. In comparison, just 19 percent of those in the coated-stent era required a second procedure, an 18 percent reduction, the researchers noted.

The overall two-year death rate in both periods was the same, 8.4 percent, but there was a reduction in the number of heart attacks (formally called ST-elevation myocardial infarctions) from 2.4 percent to 2.0 percent.

But, the overall survival of bare-metal stent recipients declined when the coated-stent era began, the study found. "Why should having a coated stent available affect the survival of bare-metal stent patients?" asked lead researcher Dr. David J. Malenka, a cardiologist at Dartmouth Medical School. "The reason is that somehow sicker patients were getting bare-metal stents."

So the study's results were affected by "selection bias," Malenka said. "Patients who got drug-eluting stents somehow were healthier and more likelier to survive," he said. In many cases, it was a matter of anatomy, he added. Patients with complex artery problems got bare-metal stents, while those with simpler anatomy got drug-coated stents.

But the bottom line is that drug-coated stents did decrease the need for new procedures when an artery became blocked again, the study found. Drug-coated stents might increase the incidence of such blockages, "but when you compare the increased risk of late thrombosis [clotting] associated with drug-eluting stents, that risk is more than counterbalanced by reducing the adverse events associated with revascularization [artery-reopening procedures]," Malenka said.

The study was funded in part by the U.S. National Institute on Aging and is published in the June 25 issue of the Journal of the American Medical Association.

While drug-coated stents are now used in perhaps 70 percent of cases, the bare-metal kind has its uses, Malenka said. "We understand that patients who get drug-eluting stents have to be on two antiplatelet [clot-preventing] drugs for at least a year," he said. "Not everyone can be able to afford them or be compliant with their use."

Dr. Kirk Garrett, clinical director of interventional cardiovascular research at Lenox Hill Hospital's Heart and Vascular Institute in New York City, said the new study helps to establish the appropriate use of drug-coated stents.

"We went through a difficult period when it appeared there might be real problems with drug-eluting stents involving clot formation, leading to deaths and heart attacks," Garrett said. "We found that, in fact, there does not seem to be an important signal of risk with drug-eluting stents around the world."

The Dartmouth report is the latest in "half a dozen studies, all of which indicate the use of drug-eluting stents is perfectly safe and does yield an important reduction in the need for further procedures," Garrett said.

The study was done before a second coated stent, Boston Scientific Corp.'s paclitaxel-coated Taxus, was marketed. The U.S. Food and Drug Administration has just approved a third model, Medtronic's Endeavor, coated with zotarolimus, and other products are in the testing pipeline.

The Dartmouth study differed in one respect from a major study done at the University of Pennsylvania, which looked at 72,000 persons who got stents during a nine-month period in 2003. That study also found a reduction in the need for new artery-opening procedures, but it also found a reduction in overall mortality.

You wouldn't necessarily expect a reduction in mortality, because most people don't die of restonosis [reclosing of an artery], Garrett said.

More information

Learn about stents from the U.S. National Library of Medicine.



SOURCES: David J. Malenka, M.D., cardiologist, Dartmouth Medical School, Lebanon N.H.; Kirk Carrett, M.D., clinical director of interventional cardiovascular research, Lenox Hill Hospital Heart and Vascular Institute, New York City; June 25, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drug-Coated Stents Go Head to Head
2. Study Finds Benefits With Drug-Coated Stents
3. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
4. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
5. Drug-Coated Balloons Keep Leg Arteries Open: Study
6. Drug-coated balloon overcomes in-stent restenosis
7. New Drug-Coated Stent Does Well in Early Trial
8. Drug-Coated Stents Still Spark Debate
9. More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
10. Nanowire coating for bone implants, stents
11. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a ... KLAS: Software & Services for HIT Implementation Support & Staffing report with an ... vendor performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
Breaking Medicine Technology: